Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 45.1% from a year ago
Total equity stood at $280.77M at the end of Q1 FY2026, down 45.1% from a year earlier and down 14.2% from the prior quarter. Over 3 fiscal years it compounded at -14.7% a year.
Context
- Total equity amounted to 64.8% of total assets at the end of Q1 FY2026, down 16.2 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -45.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 327.19M USD
- Year-over-year change
- -39.2%
- 4-year CAGR
- -10.3%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 327.19M | -39.2% |
| FY2024 | 2024-12-31 | 538.55M | -1.2% |
| FY2023 | 2023-12-31 | 544.91M | +3.4% |
| FY2022 | 2022-12-31 | 527.2M | +4.4% |
| FY2021 | 2021-12-31 | 504.93M | — |
Total Equity vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's Mar 2026 total equity of $280.77M is the 2nd highest of the 11 companies compared; the peer median is $212.54M.
- Its year-over-year change of -45.1% is the 10th highest of 11, against a peer median of -27.0%.
- Total equity amounts to 64.8% of total assets for VNDA, versus a peer median of 80.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $206.52B | +493455.8% | +25.8% | 96.1% | |
| Mar 2026 | $280.77M | -45.1% | -14.7% | 64.8% | |
| Mar 2026 | $278.88M | -27.6% | -24.0% | 70.4% | |
| Mar 2026 | $278.7M | +118.3% | +196.0% | 85.4% | |
| Mar 2026 | $270.85M | -35.1% | +12.9% | 80.7% | |
| Mar 2026 | $233.71M | -43.1% | -24.5% | 87.5% | |
| Mar 2026 | $191.36M | -18.1% | -7.5% | 78.0% | |
| Mar 2026 | $173.67M | -36.3% | +49.2% | 79.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $102.46M | -26.3% | — | 95.1% |
| Mar 2026 | $11.62M | -67.7% | -70.2% | 10.5% | |
| Mar 2026 | $10.68M | +3.9% | +37.4% | 32.3% | |
| Peer median (excluding VNDA) | $212.54M | -27.0% | +12.9% | 80.0% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 52.07M | 135.03M | 135.82M | 102.32M | 84.85M |
| Short-term Investments | 380.74M | 331.83M | 252.44M | 272.33M | 179M |
| Net Receivables | 32.47M | 33.51M | 34.16M | 47.1M | 54.58M |
| Inventory | 1.02M | 1.19M | 1.36M | 1.73M | 1.85M |
| Other Current Assets | 1 | 17.73M | 9.17M | 15.42M | 26.99M |
| Total Current Assets | 478.3M | 519.29M | 432.95M | 438.89M | 347.26M |
| Property, Plant & Equipment (Net) | 12.39M | 10.97M | 9.14M | 12.68M | 13.51M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 20.08M | 18.57M | 121.37M | 114.1M | 117.09M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 74.88M | 74.04M | 75M | 81.44M | 0 |
| Other Non-current Assets | 8.15M | 11.38M | 9.99M | 9.1M | 11.08M |
| Total Non-current Assets | 115.49M | 114.96M | 215.49M | 217.31M | 141.69M |
| Total Assets | 593.79M | 634.25M | 648.44M | 656.2M | 488.95M |
| Account Payables | 925K | 12.69M | 7.15M | 3.5M | 4.94M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 27.68M | 34.01M | 69.33M | 69.36M | 87.19M |
| Total Current Liabilities | 74.42M | 91.44M | 87.7M | 99.98M | 145.16M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.39M | 6.8M | 8.83M | 9.59M | 9.53M |
| Total Non-current Liabilities | 14.45M | 15.61M | 15.83M | 17.68M | 16.6M |
| Total Liabilities | 88.86M | 107.05M | 103.53M | 117.66M | 161.76M |
| Common Stock | 56K | 57K | 58K | 58K | 59K |
| Retained Earnings | (164.18M) | (157.9M) | (155.39M) | (174.29M) | (394.77M) |
| Accumulated OCI | (175K) | (1.19M) | (30K) | 74K | 629K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 504.93M | 527.2M | 544.91M | 538.55M | 327.19M |
| Total Debt | 12.37M | 11.14M | 9.4M | 12.36M | 12.62M |
| Net Debt | (39.71M) | (123.89M) | (126.42M) | (89.96M) | (72.23M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.